[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-liver-metastasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-liver-metastasis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100640212","a-prospective-study-of-a-subharmonic-aided-pressure-estimate-technology-for-early-prediction-of-response-to-systemic-therapy-in-colorectal-cancer-liver-metastases-100640212",false,"NCT07583381","A Prospective Study of a Subharmonic-Aided Pressure Estimate Technology for Early Prediction of Response to Systemic Therapy in Colorectal Cancer Liver Metastases","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Histologically or radiologically confirmed, initially diagnosed and have not undergone any treatment colorectal liver metastasis (CRLM).\n3. Lesion size ≤ 6 cm (preferably located adjacent to major anatomical structures such as large vessels or bile ducts).\n4. Lesion depth ≤ 10 cm on ultrasound imaging.\n5. Planned to receive guideline-recommended first-line systemic therapy.\n6. The target lesion has not undergone any prior systemic or local treatment, including surgery, ablation, embolization, targeted therapy, or investigational agents, before enrollment.\n7. Willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Inability to cooperate with contrast-enhanced ultrasound or subharmonic imaging examinations (e.g., dyspnea when lying supine or excessive out-of-plane motion).\n2. Know or suspected allergy to the contrast agent or other contraindications to its use.\n3. Target lesion not previously evaluated or managed according to standard systemic treatment protocols.\n4. Clinically unstable condition, advanced-stage disease, or patients with an unpredictable clinical course that may affect treatment tolerance or follow-up.\n5. Pregnant or breastfeeding women.\n6. Inability to understand or comply with the study protocol, including the requirement to complete follow-up visits and examinations.","ALL","18 Years",{"count":18,"type":19},107,"ESTIMATED","INTERVENTIONAL",[22],"NA","Colorectal cancer is a common type of cancer that often spreads to the liver. When cancer spreads to the liver, treatment becomes very difficult. Many patients will undergo chemotherapy to shrink the tumor. Currently, doctors use CT or MRI scans to assess the effect of chemotherapy, but these examinations usually take about 2 months to show changes in the size of the tumor.\n\nThe purpose of this study is to test whether a special type of ultrasound technology called \"contrast-enhanced subharmonic ultrasound\" can help doctors determine earlier whether chemotherapy is effective compared to conventional scans. This ultrasound detection does not use radiation and can display the blood perfusion status inside liver tumors. We will observe the changes in blood flow perfusion inside the tumor before the start of treatment and after 1-2 chemotherapy cycles to see if these changes can predict whether chemotherapy will be effective in the future.\n\nIf this test is effective, it will help doctors adjust the treatment plan more quickly, which may improve the treatment effect for colon cancer patients whose cancer cells have spread to the liver, and also help identify patients who are not responding to chemotherapy as early as possible, reducing the side effects and economic burden of patients.",[25,26,27],"Colorectal Liver Metastasis","Liver Neoplasms","Colorectal Neoplasms",[29,30,31,32,33,34],"Colorectal cancer liver metastasis","Contrast-enhanced ultrasound","Subharmonic imaging","Chemotherapy response prediction","Early treatment response","Perfusion imaging","NOT_YET_RECRUITING","2026-05-06",{"date":38,"type":39},"2026-05-13","ACTUAL",{"date":41,"type":19},"2026-06-01",{"date":43,"type":19},"2027-12-31",{"name":45,"class":46},"The First Hospital of Jilin University","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100613925","comparison-of-the-resection-site-order-in-simultaneous-approach-of-colorectal-liver-metastasis-100613925","NCT07272928","Comparison of the Resection Site Order in Simultaneous Approach of Colorectal Liver Metastasis","Comparison of the Resection Site Order in Simultaneous Approach of Colorectal Liver Metastasis. An International Multicentric Retrospective Trial.","CORSICO","Inclusion Criteria:\n\n* Adult patients diagnosed with colorectal cancer with synchronous liver metastases during the reference period, who underwent simultaneous resection.\n\nExclusion Criteria:\n\n* Simultaneous emergency resection due to symptoms of the primary tumor.\n* Presence of extrahepatic metastatic disease confirmed at the time of resection or diagnosis.\n* High surgical risk defined as an ASA risk score greater than 3.\n* At least 10 cases performed by the invited center during the study period.\n* Incomplete data or follow-up of less than 6 months.",{"count":56,"type":19},500,"OBSERVATIONAL","Colorectal cancer frequently presents with liver metastases, and complete removal of both primary and liver tumors can significantly improve survival. Simultaneous resection (SA) of the colon and liver is increasingly used and is considered safe when minor liver resections are performed, offering advantages such as shorter hospitalization, fewer complications, and faster chemotherapy initiation.\n\nHowever, the best sequence of resection, liver-first or colon-first, remains uncertain, as each has potential benefits and drawbacks, particularly regarding anastomotic healing. Minimally invasive approaches to SA show similar outcomes to open surgery, though limited data suggest that resection order may affect blood loss.",[25],"RECRUITING","2025-11-26",{"date":63,"type":39},"2025-12-09",{"date":65,"type":39},"2025-02-27",{"date":67,"type":19},"2026-08-27",{"name":69,"class":46},"Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":20,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100414589","anatomical-resection-of-liver-metastases-in-patients-with-ras-mutated-colorectal-cancer-100414589","NCT04678583","Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer","ARMANI","Inclusion Criteria:\n\n* Colorectal cancer with RAS mutation (KRAS or NRAS)\n* Colorectal liver metastases (single or multiple)\n* Planned R0 resection of liver metastases (and primary tumor, if present)\n* Anatomical and non-anatomical liver resection technically feasible\n* Male and female patients, age ≥ 18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Extrahepatic metastases\n* Planned staged liver resection (e.g. two-stage hepatectomy)\n* Diagnosis of another cancer \\\u003C 5 years prior to randomization Exceptions: curatively treated in situ cervical cancer, curatively resected non-melanoma skin cancer\n* Expected lack of compliance\n* Addiction or other illnesses which do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequences",{"count":79,"type":19},240,[22],"the ARMANI trial will test the hypothesis, if an anatomic resection (AR) improves long-term outcome vs. a non-anatomical resection (NAR) in patients undergoing surgery for RAS-mutated colorectal liver metastasis (CRLM).",[25],"2024-06-12",{"date":85,"type":39},"2024-06-13",{"date":87,"type":39},"2021-01-01",{"date":89,"type":19},"2027-12",{"name":91,"class":46},"Technische Universität Dresden",37]